Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151

Benzinga Newsdesk www.benzinga.com Positive 87.1%

Neg 0% Neu 0% Pos 87.1%

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.